RVMD MT Newswires 3 days ago Revolution Medicines Insider Sold Shares Worth $372,333, According to a Recent SEC Filing
RVMD MT Newswires 3 days ago Revolution Medicines Insider Sold Shares Worth $418,423, According to a Recent SEC Filing
RVMD MT Newswires 3 days ago Revolution Medicines Insider Sold Shares Worth $1,182,526, According to a Recent SEC Filing
RVMD MT Newswires 4 days ago Revolution Medicines Says First Patient Randomized in Phase 3 Pancreatic Cancer Trial
RVMD GlobeNewswire 4 days ago Revolution Medicines Announces First Patient Randomized in the RASolute 304 Clinical Trial of Daraxonrasib in Resectable Pancreatic Ductal Adenocarcinoma Following Adjuvant Chemotherapy
